 9 Meters Biopharma Inc NASDAQ: NMTR has acquired global development rights to LOB-0136 now known as NM-136 that targets glucose-dependent insulinotropic polypeptide GIP from Lobesity LLC. GIP is a hormone whose concentration increases significantly with overeating, leading to higher glucose absorption and greater insulin release. 